Connection

Robert Harrington to Anticoagulants

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Anticoagulants.
Robert Harrington
Connection Strength
4.955
Anticoagulants
  1. Management of Antithrombotic Therapy after Acute Coronary Syndromes. N Engl J Med. 2021 Feb 04; 384(5):452-460.
    View in: PubMed
    Score: 0.600
  2. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018 04; 198:84-90.
    View in: PubMed
    Score: 0.484
  3. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015 Mar; 8(3):424-433.
    View in: PubMed
    Score: 0.397
  4. Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. Curr Cardiol Rep. 2006 Jul; 8(4):279-81.
    View in: PubMed
    Score: 0.218
  5. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.
    View in: PubMed
    Score: 0.196
  6. Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. Thromb Haemost. 2004 Dec; 92(6):1229-31.
    View in: PubMed
    Score: 0.196
  7. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002 May 21; 105(20):2385-91.
    View in: PubMed
    Score: 0.164
  8. Antithrombotic Therapy after Acute Coronary Syndromes. Reply. N Engl J Med. 2021 05 13; 384(19):1873-1874.
    View in: PubMed
    Score: 0.153
  9. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.
    View in: PubMed
    Score: 0.135
  10. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thromb Haemost. 2018 Dec; 118(12):2046-2052.
    View in: PubMed
    Score: 0.129
  11. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 01 02; 137(1):91-94.
    View in: PubMed
    Score: 0.121
  12. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017 12; 117(12):2389-2395.
    View in: PubMed
    Score: 0.120
  13. Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. Pharm Stat. 2017 11; 16(6):445-450.
    View in: PubMed
    Score: 0.118
  14. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
    View in: PubMed
    Score: 0.117
  15. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
    View in: PubMed
    Score: 0.112
  16. Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. J Cardiovasc Pharmacol Ther. 2016 05; 21(3):227-32.
    View in: PubMed
    Score: 0.103
  17. Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2012 Jul; 34(1):143-63.
    View in: PubMed
    Score: 0.083
  18. Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, S?o Paulo, Brazil. J Thromb Thrombolysis. 2011 Aug; 32(2):242-66.
    View in: PubMed
    Score: 0.078
  19. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation. 2010 Aug 10; 122(6):614-22.
    View in: PubMed
    Score: 0.072
  20. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010 Feb; 123(2):134-40.
    View in: PubMed
    Score: 0.070
  21. Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. Am Heart J. 2009 Nov; 158(5):792-8.
    View in: PubMed
    Score: 0.069
  22. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009 Nov; 2(11):1083-91.
    View in: PubMed
    Score: 0.069
  23. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol. 2009 Sep 08; 54(11):969-84.
    View in: PubMed
    Score: 0.068
  24. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009 May 12; 119(18):2454-62.
    View in: PubMed
    Score: 0.066
  25. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 May; 28(10):1193-204.
    View in: PubMed
    Score: 0.058
  26. Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. Eur Heart J. 2007 Feb; 28(4):425-32.
    View in: PubMed
    Score: 0.057
  27. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006 Dec; 152(6):1042-50.
    View in: PubMed
    Score: 0.056
  28. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006 Dec 05; 114(23):2490-7.
    View in: PubMed
    Score: 0.056
  29. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006 Sep 07; 355(10):1006-17.
    View in: PubMed
    Score: 0.055
  30. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. J Thromb Thrombolysis. 2006 Jun; 21(3):211-20.
    View in: PubMed
    Score: 0.054
  31. Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future. Curr Hematol Rep. 2005 Sep; 4(5):397-404.
    View in: PubMed
    Score: 0.052
  32. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. Am J Cardiol. 2005 Jun 15; 95(12):1404-8.
    View in: PubMed
    Score: 0.051
  33. The potential of aptamers as anticoagulants. Trends Cardiovasc Med. 2005 Jan; 15(1):41-5.
    View in: PubMed
    Score: 0.049
  34. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004 Mar 17; 43(6):972-8.
    View in: PubMed
    Score: 0.047
  35. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003 Nov; 15(11):611-6.
    View in: PubMed
    Score: 0.045
  36. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct; 146(4):628-34.
    View in: PubMed
    Score: 0.045
  37. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003 Feb 05; 41(3):386-93.
    View in: PubMed
    Score: 0.043
  38. External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. J Thromb Thrombolysis. 2023 Feb; 55(2):211-221.
    View in: PubMed
    Score: 0.043
  39. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.
    View in: PubMed
    Score: 0.043
  40. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002 Sep 17; 106(12):1470-6.
    View in: PubMed
    Score: 0.042
  41. Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. Thromb Res. 2022 Mar; 211:63-69.
    View in: PubMed
    Score: 0.040
  42. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 04; 45(4):477-487.
    View in: PubMed
    Score: 0.033
  43. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2019 01; 94(1):21-28.
    View in: PubMed
    Score: 0.032
  44. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). Am J Cardiol. 2017 Oct 01; 120(7):1043-1048.
    View in: PubMed
    Score: 0.029
  45. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
    View in: PubMed
    Score: 0.028
  46. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.
    View in: PubMed
    Score: 0.021
  47. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006 Oct 09; 166(18):2027-34.
    View in: PubMed
    Score: 0.014
  48. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res. 2006; 117(4):439-46.
    View in: PubMed
    Score: 0.013
  49. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation. 2004 Aug 10; 110(6):679-84.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.